Benito Villalvilla, CristinaPérez Diego, MarioAngelina Querencias, AlbaKisand, KaiRebane, AnaSubiza, José LuisPalomares Gracia, Óscar2023-06-222023-06-222022-06-180091-674910.1016/j.jaci.2021.06.012https://hdl.handle.net/20.500.14352/71283CRUE-CSIC (Acuerdos Transformativos 2021)Allergoid–mannan conjugates are novel vaccines for allergen-specific immunotherapy being currently assayed in phase 2 clinical trials. Allergoid–mannan conjugates target dendritic cells (DCs) and generate functional forkhead box P3 (FOXP3)-positive Treg cells, but their capacity to reprogram monocyte differentiation remains unknown.engAtribución-NoComercial-SinDerivadas 3.0 Españahttps://creativecommons.org/licenses/by-nc-nd/3.0/es/journal articlehttps://doi.org/10.1016/j.jaci.2021.06.012open access577.1Allergen-specific immunotherapyallergoid–mannan conjugatesmonocytestolerogenic dendritic cellsregulatory T cellsmetabolismepigeneticsQuímicaBiología molecular (Química)Bioquímica (Química)23 Química